Compare Merck & Co., Inc. (MRK) vs Schlumberger NV (SLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Schlumberger NV — how do they compare? Merck & Co., Inc. trades at $130.46 (market cap $323.00B), while Schlumberger NV trades at $53.7 (market cap $78.96B). The key difference: Merck & Co., Inc. is far larger — about 4.1× Schlumberger NV's market cap, and Merck & Co., Inc. pays the higher dividend (2.6%). Which is the better fit depends on your goals.
| MRK | SLB | |
|---|---|---|
Market Cap | $323.00B | $78.96B |
Sector | Health | Energy |
52-Week High | $131.84 | $58.01 |
52-Week Low | $77.60 | $31.72 |
Enterprise Value | $369.77B | $87.68B |
Dividend Yield | 2.6% | 2.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MRK trades at $130.90, up 1.81% today, with a bullish technical signal and strong institutional buying interest. The stock shows robust fundamentals with revenue of $65.01B in 2025 and net income of $18.25B, though a high P/E of 104.74 indicates premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives.
Outlook is positive with a consensus price target of $139.90, offering ~7% upside, supported by 67.57% analyst buy ratings. Risks include integration challenges from acquisitions and patent expirations, but strong cash flow and dividend payments provide stability. Investors may find value in Merck's market leadership and pipeline expansion, though valuation metrics warrant caution.
SLB's stock trades at $50.53, down 1.96% over the past day, but maintains a bullish technical signal with strong moving average support. The company recently reported Q2 2026 earnings of $0.55 per share, beating estimates, and has a consensus analyst price target of $63.00. Revenue for 2025 was $35.71 billion, with a net income margin of 8.53% and a P/E ratio of 24.65.
The outlook for SLB is positive, driven by growth in offshore, digital, and production segments, though risks include Middle East volatility and net debt levels. With 85% of analysts rating it a buy and a dividend yield supported by recent payments, the stock presents a compelling opportunity for investors seeking energy sector exposure with solid fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Schlumberger NV
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →
